Developer docs
API playgroundTry for free, no card

Search company profiles

Octave

Full company profile

uuid000045l

Namestring
Octave
Legal namestring
Octave Bioscience, Inc.
Websiteurl
octavebio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Octave Bioscience, Inc. is a privately held precision neurology company founded in 2014 and headquartered in Menlo Park, California. Its flagship commercial product is the Octave Multiple Sclerosis Disease Activity (MSDA) Test, the first multi-protein, blood-based biomarker assay specifically designed for multiple sclerosis. The test measures 18 serum protein biomarkers across four biological pathways (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity) and applies a proprietary machine-learning algorithm — trained on thousands of prior MS patient profiles — together with patient demographics and clinical context to generate a single Disease Activity Score from 1–10. All processing occurs in a CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory, with HITRUST, ISO/IEC 27001:2022, and ISO/IEC 42001:2023 certifications governing information security and AI management.

The company generates revenue primarily through per-test unit pricing reimbursed by insurance, with in-network coverage spanning 75M+ lives and payer contracts covering 84M+ member lives. Distribution is sales-led but materially augmented by a December 2025 strategic collaboration with Quest Diagnostics, which provides blood-draw access across approximately 7,000 patient service centers nationwide, complemented by partnerships with Any Lab Test Now and ARCpoint Labs. The primary customer is the ordering neurologist or MS specialist, who uses the MSDA Test to inform disease-modifying therapy (DMT) initiation, switching, monitoring, and de-escalation decisions; patients act as end users rather than direct payers in most cases. Beyond MS, Octave is extending its biomarker platform into an in-development MS Disease Progression (MSDP) Test (funded by the Valhalla Foundation) and an in-development Parkinson's disease multi-protein biomarker panel (funded by a $10M Michael J. Fox Foundation grant), with Alzheimer's identified as a future expansion target.

Octave has raised approximately $94M+ across disclosed funding events, including a $35M Series C and $15.5M debt facility in September 2025, and is backed by Kleiner Perkins, Northpond Ventures, Section 32, Casdin Capital, Deerfield, Echo Health Ventures, Merck Global Health Innovation Fund, Novartis (drX), Hikma, Intermountain, and the BlueCross BlueShield Fund (Sandbox Industries). Strategic pharmaceutical relationships include a Merck GHI investment and a multi-asset collaboration with TG Therapeutics generating real-world evidence for ublituximab (BRIUMVI). As of April 2026, the company reported 29,000+ scores delivered to 500+ prescribers across 20,000+ patients, with all 50 U.S. states served and a projected 300% annual growth rate for 2026.

Short descriptiontext

Octave Bioscience is a precision neurology company whose flagship MSDA Test uses an 18-biomarker serum assay and proprietary ML algorithm to generate a 1–10 multiple sclerosis disease activity score from a single blood draw, sold to U.S. neurologists via a sales-led motion and distributed through Quest Diagnostics' 7,000+ phlebotomy sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based biomarker diagnostics, multiple sclerosis testing, neurodegenerative disease diagnostics, precision neurology, clinical laboratory testing
Industry3 codes
PRIMARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAFAA
Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Diagnostic Services
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic test sales (per-test unit pricing)
TypeTransaction Fee
Description

Revenue is generated per MSDA Test ordered and processed. The test is paid primarily through reimbursement from insurance (Octave accepts all insurances) with patients paying any remaining out-of-pocket balance. Flexible payment plans and the Octave Cares financial assistance program are offered for eligible patients. Reimbursement is in-network for 75M+ lives (as of 2025) and payer contracts cover 84M+ member lives.

octavebio.com
2Quest Diagnostics channel volume
TypeTransaction Fee
Description

After December 2025 partnership with Quest Diagnostics, a portion of revenue scales with test volume referred through Quest's ~7,000 patient service centers nationwide, expanding patient access and billable test volume.

octavebio.com
3Non-dilutive grant funding (R&D)
TypeLicensing Royalties
Description

Non-revenue but material capital source: $10M grant from The Michael J. Fox Foundation for Parkinson's biomarker development and Valhalla Foundation grant funding for the MSDP (MS disease progression) Test development. These fund R&D pipeline expansion rather than commercial sales.

finsmes.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1Insurance-billed diagnostic test with patient financial assistance
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Per-test unit pricing not publicly disclosed. All insurances accepted. Octave Cares financial assistance program available for eligible patients; flexible payment plans offered for any remaining patient balance. Average results turnaround of 4 business days from sample receipt.

octavebio.com
2Patient self-pay / out-of-pocket option
ModelOtherBilling cadencePay-as-you-go
Notes

Out-of-pocket cost varies by insurance coverage; preliminary financial assistance qualification available via the Octave Cares program. Patients commonly repeat testing every 3-6 months for longitudinal monitoring.

octavebio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1MSDA Test
Description

Octave's flagship multi-protein, blood-based biomarker test for multiple sclerosis disease activity, generating a 1-10 Disease Activity Score from 18 serum protein biomarkers across four biological pathways.

octavebio.com
+1 more record
Core offering1 text field

Octave develops, validates, and delivers blood-based multi-protein biomarker diagnostic tests for neurodegenerative diseases. Its flagship commercially available product, the Octave MSDA Test, is a serum assay that measures 18 protein biomarkers across 4 biological pathways and uses a machine-learning algorithm to generate a personalized 1-10 Disease Activity Score for multiple sclerosis. The same platform underpins in-development products for MS disease progression (MSDP Test) and Parkinson's disease, with all samples processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved clinical laboratory.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 1 in 5 documented clinical-decision changes after MSDA testing
+7 more records
Product overview1 text field

Octave Bioscience is a precision neurology company built around a single unified biomarker-testing platform that converts blood-based multi-protein measurements into quantitative disease activity and (eventually) disease progression scores. Its commercially available flagship is the Octave MSDA Test for multiple sclerosis, which underlies and is the first productized output of the underlying Octave Care Management Platform for neurodegenerative diseases. The same platform architecture is being extended to additional pipeline products: the in-development MSDP Test for MS disease progression (funded by the Valhalla Foundation) and the in-development Parkinson's Disease Biomarker Panel (funded by The Michael J. Fox Foundation), with Alzheimer's identified as a future extension. All tests are processed in a CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory, with samples collected via a partner phlebotomy network including Quest Diagnostics (7,000+ sites) and Any Lab Test Now.

Product and service3 records
1Octave MSDA Test (Multiple Sclerosis Disease Activity Test)
CategoryCore commercial diagnostic test
Description

Flagship commercially available multi-protein, blood-based biomarker assay for multiple sclerosis that measures 18 serum protein biomarkers across 4 biological pathways (Immunomodulation, Neuroinflammation, Myelin Biology, Neuroaxonal Integrity) and uses a machine-learning algorithm to generate a personalized Disease Activity Score from 1-10 for ordering U.S. neurologists and MS specialists, supporting DMT initiation, switching, monitoring, and treatment optimization. Processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory.

2MSDP Test (Multiple Sclerosis Disease Progression Test)
CategoryIn-development pipeline diagnostic test
Description

In-development blood-based biomarker test designed to provide an objective measure of multiple sclerosis disease progression across multiple MS types, intended to inform earlier treatment decisions. Development is supported by a grant from the Valhalla Foundation.

3Parkinson's Disease Biomarker Panel
CategoryIn-development pipeline diagnostic test
Description

In-development world's-first multi-protein, blood-based assay for Parkinson's disease, funded by a $10 million grant from The Michael J. Fox Foundation, with the goal of improving disease assessment, research, and management of neurodegenerative disease.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-02
Description

Octave Bioscience formed a strategic collaboration with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest's nationwide network of approximately 7,000 patient access sites in the United States. The partnership aims to improve diagnosis and management of MS by providing a reliable blood test for disease activity, and establishes a pathway for future tests from Octave's neurology portfolio.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-10-14
Description

Codeword, a communications and marketing agency, added Octave to its client roster alongside Demandbase and Root Insurance. The engagement supports brand narrative, market leadership positioning, and strategic communication during product launches.

3Accelerated Cure Project for Multiple Sclerosis (ACP)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Long-standing partnership with the Accelerated Cure Project for Multiple Sclerosis. ACP's Chief Scientific Officer Stephanie Buxhoeveden highlights the collaboration as enabling demonstration of proteomic associations with clinically defined relapse in MS, which was crucial for developing the MSDA Test.

octavebio.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

TG Therapeutics presented clinical data generated with the Octave MSDA Test for its FDA-approved MS drug BRIUMVI (ublituximab-xiiy) at ACTRIMS Forum 2026, including real-world infusion experience from the ENABLE Phase 4 observational study. Octave also presented a poster on multi-protein biomarker test results from the ENHANCE study of ublituximab at ACTRIMS 2026.

Strategic tierStrategicTypeChannel Partner/ Reseller/ Distributor
Description

Any Lab Test Now is part of Octave's nationwide partner lab draw network; the Octave website provides a searchable state-by-state directory of Any Lab Test Now and ARCpoint Labs locations for blood draws.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Operates the Simoa single-molecule-array platform for ultra-sensitive blood-based protein biomarker detection, the closest architectural analog to Octave's multi-analyte serum biomarker approach, with overlapping neuroscience and neurodegeneration applications.

TypeDirect peer
Description

Provides multiplexed electrochemiluminescence immunoassay platforms for simultaneous measurement of multiple protein biomarkers in serum, directly comparable to Octave's 18-biomarker panel and Disease Activity Score use case.

TypeBroad incumbent
Description

Established molecular-diagnostics company with a specialty-lab commercial model, payer-reimbursement infrastructure, and clinician-direct sales motion, comparable to Octave's go-to-market but with a genetic rather than proteomic focus.

TypeBroad incumbent
Description

Specialty lab with proprietary molecular assays, in-network commercial-payer coverage, and a direct-to-clinician sales model, structurally analogous to Octave's commercial motion in a different indication area.

TypeBroad incumbent
Description

Specialty diagnostics company that combines proprietary genomic assays with a clinical-utility evidence-generation strategy to drive payer coverage and clinician adoption, a comparable commercial playbook to Octave's MSDA Test.

TypeBroad incumbent
Description

Immune-profiling diagnostics company with a CLIA-certified lab, payer coverage, and pharma partnerships, sharing the specialty-lab + clinical-evidence + strategic-partner model with Octave.

TypeBroad incumbent
Description

Global in-vitro diagnostics incumbent with broad neurology and immunology assay menus, including MS-related biomarkers; represents the large-pharma competitive backdrop against which Octave must position its specialty multi-analyte test.

8Abbott Diagnostics
TypeBroad incumbent
Description

Major diagnostics incumbent with neurology and immunology assay franchises and a global clinical-lab footprint, a relevant strategic-comparator and potential partner/acquirer for a specialty neurodegenerative-diagnostics player like Octave.

TypeBroad incumbent
Description

Broad in-vitro diagnostics platform with established neurology and specialty-assay channels in US hospital and reference-lab networks, a relevant incumbent comparator for Octave's specialty-lab positioning.

TypeBroad incumbent
Description

Specialty molecular-diagnostics company now within Roche, demonstrating the specialty-lab-to-pharma-strategic-exit pathway that Octave's platform-extension and pharma-investor base could also pursue.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Octave

Clinical Diagnostic Servicesoctavebio.com

Octave Bioscience is a precision neurology company whose flagship MSDA Test uses an 18-biomarker serum assay and proprietary ML algorithm to generate a 1–10 multiple sclerosis disease activity score from a single blood draw, sold to U.S. neurologists via a sales-led motion and distributed through Quest Diagnostics' 7,000+ phlebotomy sites.

What Octave does

Octave Bioscience, Inc. is a privately held precision neurology company founded in 2014 and headquartered in Menlo Park, California. Its flagship commercial product is the Octave Multiple Sclerosis Disease Activity (MSDA) Test, the first multi-protein, blood-based biomarker assay specifically designed for multiple sclerosis. The test measures 18 serum protein biomarkers across four biological pathways (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity) and applies a proprietary machine-learning algorithm — trained on thousands of prior MS patient profiles — together with patient demographics and clinical context to generate a single Disease Activity Score from 1–10. All processing occurs in a CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory, with HITRUST, ISO/IEC 27001:2022, and ISO/IEC 42001:2023 certifications governing information security and AI management.

The company generates revenue primarily through per-test unit pricing reimbursed by insurance, with in-network coverage spanning 75M+ lives and payer contracts covering 84M+ member lives. Distribution is sales-led but materially augmented by a December 2025 strategic collaboration with Quest Diagnostics, which provides blood-draw access across approximately 7,000 patient service centers nationwide, complemented by partnerships with Any Lab Test Now and ARCpoint Labs. The primary customer is the ordering neurologist or MS specialist, who uses the MSDA Test to inform disease-modifying therapy (DMT) initiation, switching, monitoring, and de-escalation decisions; patients act as end users rather than direct payers in most cases. Beyond MS, Octave is extending its biomarker platform into an in-development MS Disease Progression (MSDP) Test (funded by the Valhalla Foundation) and an in-development Parkinson's disease multi-protein biomarker panel (funded by a $10M Michael J. Fox Foundation grant), with Alzheimer's identified as a future expansion target.

Octave has raised approximately $94M+ across disclosed funding events, including a $35M Series C and $15.5M debt facility in September 2025, and is backed by Kleiner Perkins, Northpond Ventures, Section 32, Casdin Capital, Deerfield, Echo Health Ventures, Merck Global Health Innovation Fund, Novartis (drX), Hikma, Intermountain, and the BlueCross BlueShield Fund (Sandbox Industries). Strategic pharmaceutical relationships include a Merck GHI investment and a multi-asset collaboration with TG Therapeutics generating real-world evidence for ublituximab (BRIUMVI). As of April 2026, the company reported 29,000+ scores delivered to 500+ prescribers across 20,000+ patients, with all 50 U.S. states served and a projected 300% annual growth rate for 2026.

Octave firmographics

Firmographics
Name
Octave
Legal name
Octave Bioscience, Inc.
Website
https://octavebio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Octave Bioscience is a precision neurology company whose flagship MSDA Test uses an 18-biomarker serum assay and proprietary ML algorithm to generate a 1–10 multiple sclerosis disease activity score from a single blood draw, sold to U.S. neurologists via a sales-led motion and distributed through Quest Diagnostics' 7,000+ phlebotomy sites.
Ownership category
akta.pro rank

Octave industry classification

Industry
Product category
Clinical Diagnostic Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAFAA
Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Blood-based biomarker diagnostics
  • Multiple sclerosis testing
  • Neurodegenerative disease diagnostics
  • Precision neurology
  • Clinical laboratory testing

Where Octave is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Octave business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Diagnostic test sales (per-test unit pricing): Revenue is generated per MSDA Test ordered and processed. The test is paid primarily through reimbursement from insurance (Octave accepts all insurances) with patients paying any remaining out-of-pocket balance. Flexible payment plans and the Octave Cares financial assistance program are offered for eligible patients. Reimbursement is in-network for 75M+ lives (as of 2025) and payer contracts cover 84M+ member lives.
  2. Quest Diagnostics channel volume: After December 2025 partnership with Quest Diagnostics, a portion of revenue scales with test volume referred through Quest's ~7,000 patient service centers nationwide, expanding patient access and billable test volume.
  3. Non-dilutive grant funding (R&D): Non-revenue but material capital source: $10M grant from The Michael J. Fox Foundation for Parkinson's biomarker development and Valhalla Foundation grant funding for the MSDP (MS disease progression) Test development. These fund R&D pipeline expansion rather than commercial sales.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goInsurance-billed diagnostic test with patient financial assistance
OtherPay-as-you-goPatient self-pay / out-of-pocket option

Go-to-market motion4 records

Distribution channels1 record

Marketing channels9 records

Octave product offering

Product offering

Core offering

Octave develops, validates, and delivers blood-based multi-protein biomarker diagnostic tests for neurodegenerative diseases. Its flagship commercially available product, the Octave MSDA Test, is a serum assay that measures 18 protein biomarkers across 4 biological pathways and uses a machine-learning algorithm to generate a personalized 1-10 Disease Activity Score for multiple sclerosis. The same platform underpins in-development products for MS disease progression (MSDP Test) and Parkinson's disease, with all samples processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved clinical laboratory.

Product overview

Octave Bioscience is a precision neurology company built around a single unified biomarker-testing platform that converts blood-based multi-protein measurements into quantitative disease activity and (eventually) disease progression scores. Its commercially available flagship is the Octave MSDA Test for multiple sclerosis, which underlies and is the first productized output of the underlying Octave Care Management Platform for neurodegenerative diseases. The same platform architecture is being extended to additional pipeline products: the in-development MSDP Test for MS disease progression (funded by the Valhalla Foundation) and the in-development Parkinson's Disease Biomarker Panel (funded by The Michael J. Fox Foundation), with Alzheimer's identified as a future extension. All tests are processed in a CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory, with samples collected via a partner phlebotomy network including Quest Diagnostics (7,000+ sites) and Any Lab Test Now.

Differentiator

Problem solved

Functional benefit

Brands

  • MSDA Test: Octave's flagship multi-protein, blood-based biomarker test for multiple sclerosis disease activity, generating a 1-10 Disease Activity Score from 18 serum protein biomarkers across four biological pathways.
  • MSDP Test

Products and services

  • Octave MSDA Test (Multiple Sclerosis Disease Activity Test) Flagship commercially available multi-protein, blood-based biomarker assay for multiple sclerosis that measures 18 serum protein biomarkers across 4 biological pathways (Immunomodulation, Neuroinflammation, Myelin Biology, Neuroaxonal Integrity) and uses a machine-learning algorithm to generate a personalized Disease Activity Score from 1-10 for ordering U.S. neurologists and MS specialists, supporting DMT initiation, switching, monitoring, and treatment optimization. Processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory.
  • MSDP Test (Multiple Sclerosis Disease Progression Test) In-development blood-based biomarker test designed to provide an objective measure of multiple sclerosis disease progression across multiple MS types, intended to inform earlier treatment decisions. Development is supported by a grant from the Valhalla Foundation.
  • Parkinson's Disease Biomarker Panel In-development world's-first multi-protein, blood-based assay for Parkinson's disease, funded by a $10 million grant from The Michael J. Fox Foundation, with the goal of improving disease assessment, research, and management of neurodegenerative disease.

Quantifiable outcome

  • 1 in 5 documented clinical-decision changes after MSDA testing
  • +7 more outcomes

Companies that use Octave

Customer profile

Segments4 records

Ideal customer profiles2 records

Octave technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Octave partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, minor and strategic.

  • Quest DiagnosticsflagshipChannel Partner/ Reseller/ Distributor · 2 December 2025Octave Bioscience formed a strategic collaboration with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest's nationwide network of approximately 7,000 patient access sites in the United States. The partnership aims to improve diagnosis and management of MS by providing a reliable blood test for disease activity, and establishes a pathway for future tests from Octave's neurology portfolio.
  • CodewordminorGTM or Marketing Partner · 14 October 2025Codeword, a communications and marketing agency, added Octave to its client roster alongside Demandbase and Root Insurance. The engagement supports brand narrative, market leadership positioning, and strategic communication during product launches.
  • Accelerated Cure Project for Multiple Sclerosis (ACP)strategicStrategic or Co-development PartnerLong-standing partnership with the Accelerated Cure Project for Multiple Sclerosis. ACP's Chief Scientific Officer Stephanie Buxhoeveden highlights the collaboration as enabling demonstration of proteomic associations with clinically defined relapse in MS, which was crucial for developing the MSDA Test.
  • TG TherapeuticsstrategicStrategic or Co-development PartnerTG Therapeutics presented clinical data generated with the Octave MSDA Test for its FDA-approved MS drug BRIUMVI (ublituximab-xiiy) at ACTRIMS Forum 2026, including real-world infusion experience from the ENABLE Phase 4 observational study. Octave also presented a poster on multi-protein biomarker test results from the ENHANCE study of ublituximab at ACTRIMS 2026.
  • Any Lab Test NowstrategicChannel Partner/ Reseller/ DistributorAny Lab Test Now is part of Octave's nationwide partner lab draw network; the Octave website provides a searchable state-by-state directory of Any Lab Test Now and ARCpoint Labs locations for blood draws.

Scale indicators15 records

Recent moves6 records

Expansion highlights7 records

Octave competitors and assessment

Company assessment

Direct peers

  • Quanterix Corporation: Operates the Simoa single-molecule-array platform for ultra-sensitive blood-based protein biomarker detection, the closest architectural analog to Octave's multi-analyte serum biomarker approach, with overlapping neuroscience and neurodegeneration applications.
  • Meso Scale Diagnostics: Provides multiplexed electrochemiluminescence immunoassay platforms for simultaneous measurement of multiple protein biomarkers in serum, directly comparable to Octave's 18-biomarker panel and Disease Activity Score use case.

Broad incumbents

  • Myriad Genetics: Established molecular-diagnostics company with a specialty-lab commercial model, payer-reimbursement infrastructure, and clinician-direct sales motion, comparable to Octave's go-to-market but with a genetic rather than proteomic focus.
  • Natera: Specialty lab with proprietary molecular assays, in-network commercial-payer coverage, and a direct-to-clinician sales model, structurally analogous to Octave's commercial motion in a different indication area.
  • Veracyte: Specialty diagnostics company that combines proprietary genomic assays with a clinical-utility evidence-generation strategy to drive payer coverage and clinician adoption, a comparable commercial playbook to Octave's MSDA Test.
  • Adaptive Biotechnologies: Immune-profiling diagnostics company with a CLIA-certified lab, payer coverage, and pharma partnerships, sharing the specialty-lab + clinical-evidence + strategic-partner model with Octave.
  • Roche Diagnostics: Global in-vitro diagnostics incumbent with broad neurology and immunology assay menus, including MS-related biomarkers; represents the large-pharma competitive backdrop against which Octave must position its specialty multi-analyte test.
  • Abbott Diagnostics: Major diagnostics incumbent with neurology and immunology assay franchises and a global clinical-lab footprint, a relevant strategic-comparator and potential partner/acquirer for a specialty neurodegenerative-diagnostics player like Octave.
  • Siemens Healthineers: Broad in-vitro diagnostics platform with established neurology and specialty-assay channels in US hospital and reference-lab networks, a relevant incumbent comparator for Octave's specialty-lab positioning.
  • Foundation Medicine (Roche): Specialty molecular-diagnostics company now within Roche, demonstrating the specialty-lab-to-pharma-strategic-exit pathway that Octave's platform-extension and pharma-investor base could also pursue.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

Octave social profiles

Digital presence

Octave compliance and trust

Trust signal

Compliance8 records

Octave financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Octave leadership team

Management profile

Number of profiles

Profiles15 records

Octave funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Octave M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Octave

What does Octave do?

Octave develops, validates, and delivers blood-based multi-protein biomarker diagnostic tests for neurodegenerative diseases. Its flagship commercially available product, the Octave MSDA Test, is a serum assay that measures 18 protein biomarkers across 4 biological pathways and uses a machine-learning algorithm to generate a personalized 1-10 Disease Activity Score for multiple sclerosis. The same platform underpins in-development products for MS disease progression (MSDP Test) and Parkinson's disease, with all samples processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved clinical laboratory.

Is Octave a public or private company?

Octave is a private company. It is classified as venture growth investor backed and is currently operating.

When was Octave founded?

Octave was founded in 2014. It employs 51 to 100 people.

Where is Octave based?

Octave is headquartered in Menlo Park, United States, in the North America region.

How does Octave make money?

Three revenue lines are on record. Diagnostic test sales (per-test unit pricing) is the primary driver. The others are quest Diagnostics channel volume and non-dilutive grant funding (R&D).

Who are Octave's main competitors?

Direct peers on record are Quanterix Corporation and Meso Scale Diagnostics. Broad incumbents are Myriad Genetics, Natera, Veracyte, Adaptive Biotechnologies, Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers and Foundation Medicine (Roche).

Does Octave have an API?

No public API is recorded for Octave.

What industry is Octave in?

Octave's product category is Clinical Diagnostic Services. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring), with a secondary code of HLACAFAA, Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceOctave Bioscience Names Jennifer Mellum Vice President of Marketing as Precision Neurology Platform ScalesOctave Bioscience appointed Jennifer Mellum as Vice President of Marketing, joining as the company scales its Parkinson's disease blood test with the Michael J. Fox Foundation. Mellum brings over 20 years of marketing leadership, including roles at GRAIL, GeneDx, and Prime Therapeutics. The appointment follows two other senior commercial hires in 2026.AInvestOctave Bioscience Is Hiring a Commercial Team. The Harder Part Comes Next.Octave Bioscience hired three senior commercial executives in eight months, including SVP Kirk Stockwood, VP Zachary Fernandes, and VP Jennifer Mellum. The company reported $19.1 million in 2023 revenue, with roughly $97 million in total capital. The next financing decision and revenue growth will determine whether the commercial hires succeed.Neurology liveGauging MS Disease Activity Through Octave’s MSDA Test: Taylor Gonyou, DOOctave Bio's MSDA test, which utilizes an algorithm of 18 biomarkers to assess multiple sclerosis disease activity, was presented at the 2023 ACTRIMS Forum by researchers led by Dr. Taylor Gonyou. The presentation detailed findings from five real-world cases demonstrating how the test's pathway scores reconcile with clinical and radiographic evidence to support patient management. This development introduces a precision medicine approach for establishing baselines and monitoring MS patients longitudinally.Neurology liveReal-World Analysis Shows Growing Use of Octave’s MS Disease Activity Test in Clinical PracticeA retrospective analysis presented at the 2025 CMSC Annual Meeting reveals that Octave’s Multiple Sclerosis Disease Activity (MSDA) test has been utilized in 12,833 instances across 122 US institutions since its commercial launch in 2022. The data indicates that the test influenced disease-modifying therapy decisions for 44% of the analyzed patient cohort and demonstrated varying efficacy correlations with treatments like ublituximab and teriflunomide. Researchers concluded that while the tool shows promise for monitoring MS activity, further study is required to fully integrate it into standard clinical workflows.BioSpaceNew Independent Study Establishes the Octave MSDA Test as an Objective Measure to Distinguish True MS Relapse from PseudoexacerbationOctave Bioscience announced the publication of an independent study in Neurology and Therapy validating its Octave MSDA Test for distinguishing true multiple sclerosis relapses from pseudoexacerbations. The retrospective study demonstrated that the test achieved 100% sensitivity and 94% specificity, significantly outperforming neurofilament light biomarkers in identifying MRI-confirmed active inflammatory disease.FinancialContent Business PageNew Independent Study Establishes the Octave MSDA Test as an Objective Measure to Distinguish True MS Relapse from PseudoexacerbationOctave Bioscience announced publication of an independent study in Neurology and Therapy evaluating its Multiple Sclerosis Disease Activity (MSDA) Test in distinguishing true inflammatory relapse from pseudoexacerbation. The retrospective observational study enrolled 66 people with relapsing MS at UT Southwestern Medical Center and found the MSDA Test achieved 100% sensitivity, 94% specificity, and 100% negative predictive value, outperforming neurofilament light chain biomarkers. The blood test provides objective, quantifiable data to help clinicians determine when MRI or corticosteroid treatment is warranted for the nearly one million Americans living with MS.MorningstarNew Independent Study Establishes the Octave MSDA Test as an Objective Measure to Distinguish True MS Relapse from PseudoexacerbationAn independent study published in Neurology and Therapy evaluated the Octave MSDA Test in 66 MS patients, finding it identified MRI-confirmed active disease with 100% sensitivity, 94% specificity, and 100% negative predictive value. The test outperformed neurofilament light (AUC 98.1% vs 82.8%) and was obtained before MRI 79% of the time.BioSpaceOctave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic PartnershipsOctave Bioscience appointed Zachary Fernandes as Vice President of Business Development to lead partnership strategy. He brings over 15 years of experience, including roles at Quanterix and Simoa Diagnostics. The company plans to launch a Parkinson's multi-analyte blood test later this year.Business Wire BlogOctave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic PartnershipsOctave Bioscience appointed Zachary Fernandes as Vice President of Business Development to lead partnership strategy. Fernandes brings over 15 years of experience, including roles at Quanterix and Simoa Diagnostics. He will help scale Octave's Parkinson's multi-analyte blood test, launching later this year.MarketScreenerHexagon spinoff Octave begins trading on Nasdaq Stockholm todayHexagon spinoff Octave began trading on Nasdaq Stockholm today via Swedish Depository Receipts (SDRs) under ticker OCTV SDB. The company also listed shares in New York, which started trading on May 21 on a 'when-issued' basis, with regular-way trading scheduled to begin on May 28.